Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy

Taborelli, Martina; Sozzi, Michele; Zotto, Stefania Del; Toffolutti, Federica; Montico, Marcella; Zanier, Loris; Serraino, Diego

doi:10.1371/journal.pone.0235142

Cited by 21 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, thyroid is also not ignored in IBD surveillance. And an elevated risk of kidney cancer in our data was consistent with a cohort study in northeastern Italy by Taborelli et al 30 . The reported possible mechanisms involves the increased occurrence of chronic kidney disease 31 or potential nephrotoxic drugs such as thiopurines 32 …”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Risk of malignancy in patients with inflammatory bowel disease: A population‐based cohort study from China

Zhang

Chen

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Carcinogenesis is one of the major complications for patients with inflammatory bowel disease (IBD) and causes poor prognosis. We aimed to describe cancer incidence in the Chinese IBD cohort compared to general population-based cancer registration data and further explore associated risk factors for cancer occurrence in IBD patients. IBD inpatients from January 1998 to January 2018 in Peking Union Medical College Hospital (PUMCH) were included in our study. Patients were followed-up from the date of IBD diagnosis until either the date of first cancer diagnosis or January 2019. Standardized incidence ratios (SIRs) of overall cancer and site-specific cancers were calculated.A total of 869 Ulcerative Colitis (UC) and 516 Crohn's disease (CD) patients were finally included with median follow-up time of 7 and 5 years, respectively. Fifty-three cases developed malignancies. After standardization by age and gender, SIR of total cancer occurrence in IBD patients was 1.77 (95% CI, 1.33-2.32). As for UC, digestive cancers (SIR 3.75; 95% CI, 2.29-5.80), thyroid cancer (SIR 10.34; 95% CI, and hematological malignancies (SIR 6.25; 95% CI, 1.68-16.00) had the highest incidence, which were prominent in young and middle-aged patients. Use of steroids, immunosuppressants or infliximab did not present higher risk of malignancies in UC patients. There was no significant difference in cancer risk between CD patients and general population. In conclusion, the increased risks of multiple cancers are particularly prominent in Chinese UC patients and these findings can provide more targeted guidance for cancer monitoring in Chinese IBD patients.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Taborelli et al 30 The reported possible mechanisms involves the increased occurrence of chronic kidney disease 31 or potential nephrotoxic drugs such as thiopurines. 32 Specifically, in our study, the increased risk of malignancies in UC patients mainly concentrated on young and middle-aged patients.…”

Section: Discussionmentioning

confidence: 99%

Risk of malignancy in patients with inflammatory bowel disease: A population‐based cohort study from China

Zhang

Chen

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…However, analysis of two included studies that stratified for disease extent at diagnosis demonstrated that those with colonic disease location had a SIR of 4.3 (2.0–9.4) [14], comparable to the SIR found in the present study. In contrast, a recent population‐based cohort study from Italy showed no increased risk of CRC in a group of 1306 patients with CD [8]. A nationwide cohort study from Denmark following 14,463 CD patients published in 2012 reported a relative risk of 0.85 (95% CI 0.67–1.07) compared with the general population [5].…”

Section: Discussionmentioning

confidence: 99%

The long‐term incidence of dysplasia and colorectal cancer in a Crohn’s colitis population‐based cohort

et al. 2021

View full text Add to dashboard Cite

Aim The risk of developing colorectal cancer (CRC) in Crohn's disease (CD) has been variably reported. Chronic inflammation is associated with an increased risk of neoplasia; variable outcomes in CD possibly reflect the heterogeneous nature of the disease. The aim of this work was to characterize the risk of CRC in a New Zealand population‐based cohort of CD patients with colonic inflammation. Method A review of all participants with CD in the population‐based Canterbury Inflammatory Bowel Disease Study was conducted. Data on demographics, endoscopic surveillance, presence of dysplasia/neoplasia and oncological outcome were extracted. The age‐adjusted standardized incidence ratio (SIR) was used to compare the incidence of CRC in the cohort with the incidence of CRC in the New Zealand population in 2006. Results Data on 649 patients with CD were collected. Four hundred and thirty‐six participants (58% female) with ileocolonic or colonic CD were included for analysis. CRC was diagnosed in 13 patients (62% female). The median age at CRC diagnosis was 58.5 years, and the mean duration of CD prior to diagnosis of CRC was 20.4 years. When compared with the New Zealand population (using census data), the overall age‐adjusted SIR was 4.1 (95% CI 2.4–7.1). Conclusion This population‐based cohort of patients with colonic CD shows a significantly increased risk of CRC compared with the general population. This is consistent with the colonic location of inflammation increasing the risk of neoplasia. Inclusion of patients with isolated upper gastrointestinal/ileal CD in similar studies may mask the truly increased risk for patients with long‐standing colonic inflammation.

show abstract

“…CD patients are more likely to develop extraintestinal malignancies than UC patients. Upper GI cancer, lung cancer, urinary bladder cancer, skin squamous cell cancer, breast cancer were more frequent among CD patients and liverbiliary cancer, leukaemia, breast cancer and corpus uteri cancer among UC patients (5,13,14).…”

Section: Introductionmentioning

confidence: 94%

“…Ulcerative colitis (UC) and Crohn's disease (CD) are life long diseases with a chronic inflammation of the gast rointestinal (GI) tract. Patients with inflammatory bowel disease (IBD) have an increased risk to develop malig nant neoplasms, particularly colorectal cancer (CRC) in ulcerative colitis and colon Crohn's disease because of the chronic intestinal inflammation, however recent stu dies suggest the rate is decreasing thanks to improved surveillance (1)(2)(3)(4)(5)(6)(7). Colorectal cancer is the third most common cancer worldwide and accounts for 1015% of all deaths in IBD (8).…”

Section: Introductionmentioning

confidence: 99%

IBD-related Malignancies Observed in 2015–2019 : 4 Years’ Results from the Prospective, Nationwide Hungarian Registry IBD-related Malignancies – Hungarian Registry

Milassin¹,

Rutka²,

Szűcs³

et al. 2021

CEU-JGH

View full text Add to dashboard Cite

Introduction: Patients with inflammatory bowel disease (IBD) have an increased risk to develop malignant neoplasms. Neither the exact mechanism, nor the frequency of different malignancies is completely clear. Our aim was to assess the IBD associated malignancies, to collect clinical and mortality data and to analyse possible risk factors. Methods: Data on malignancies developed between January 2015 and May 2019 in Hungarian IBD patients was recorded. Every member of the Hungarian Society of Gastroenterology was prospectively interviewed. The following data were collected: demographic data, disease characteristics, previous therapy, patient adherence, type and localisation of malignancies. Results: 140 IBD patients with newly diagnosed malignancies were reported. 61.4%, 35.7%, and 2.9% of the patients had ulcerative colitis (UC), Crohn’s disease (CD) and indeterminate colitis, respectively. The mean latency was 15.2±10.5 years. Colorectal cancer (CRC) was the most common cancer (49.6%, 70). 72.9% (51/70) of them was associated with UC, more than 80% had extensive (50.9%, 26) and left-sided (31.2%, 16) colitis. The most frequent CRC localisation was the rectosigmoid colon in UC (54.9%), and the rectum in CD (38.9%). The most common non-CRC malignancies were non-melanotic skin-cancer, haematological and pulmonary cancer. Disease duration at the time of the diagnosis of malignancy was lower (17.9±10.7 versus 12.6±9.7 years); mean age at the time of the death was higher (49.3±9.4 versus 64.3±16.4 years); and survival was longer after the diagnosis of extraintestinal malignancy than CRC (0.73±1.01 versus 1.2±0.8). Summary: CRC presented typically in the distal part of the colon by male UC patients with pancolitis or left-sided colitis with a long-standing disease course of IBD. The most common non-CRC malignancies were non-melanotic skin cancer, haematological cancer and lung cancer. Non-CRC malignancies developed typically in female patients, older than CRC patients with shorter disease-course of IBD and longer survival times.

show abstract

Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy

Cited by 21 publications

References 47 publications

Risk of malignancy in patients with inflammatory bowel disease: A population‐based cohort study from China

Risk of malignancy in patients with inflammatory bowel disease: A population‐based cohort study from China

The long‐term incidence of dysplasia and colorectal cancer in a Crohn’s colitis population‐based cohort

IBD-related Malignancies Observed in 2015–2019 : 4 Years’ Results from the Prospective, Nationwide Hungarian Registry IBD-related Malignancies – Hungarian Registry

Contact Info

Product

Resources

About